You just read:

Tolerx and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer Treatment

News provided by

Tolerx, Inc.

Dec 01, 2010, 07:00 EST